Therefore, in light of the results obtained, we can postulate that treatment with Csn-B (and consequently activation of NR4A1) controls the spread of viral infection and also protects from morbidity and from excessive lung inflammation induced by IAV infection. Here, NR4A1 is linked to viral infectious disease.